Zynerba Pharmaceuticals

Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events....

Drug development,cannabinoids,fragile x syndrome,epilepsy,specialty pharmaceuticals,fragile x,and transdermal gel

Zynerba pharmaceuticals operates in the Pharmaceutical manufacturing industry.

Zynerba pharmaceuticals's revenue is 501m - 1b

Zynerba pharmaceuticals has 11 - 50 employees.